¿ìè¶ÌÊÓƵ

American Cancer Society. Cancer Facts and Figures 2016. Atlanta, Ga: American Cancer Society; 2016.

American Cancer Society. Cancer Facts and Figures 2017. Atlanta, Ga: American Cancer Society; 2017.

American Joint Committee on Cancer. Soft tissue sarcoma. In: American Joint Committee on Cancer Staging Manual. 7th Edition. New York: Springer; 2010: 291-296.

Bhangu A, Broom L, Nepogodiev D, Gourevitch D, Desai A. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review. Eur J Surg Oncol. 2013 Apr;39(4):311-9. Epub 2013 Jan 23.

Benjamin R, Pisters PWT, Helman LJ, et al. Sarcomas of soft tissue. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG. Clinical Oncology. Philadelphia, PA. Elsevier: 2008: 2009-2056.

Singer S, Maki R, O’Sullivan B. Soft tissue sarcoma In: DeVita VT, Heilman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1533-1577.

Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010 Oct 1;16(19):4884−4891.

Clark MA, Fisher C, Judson I, et al. Soft-tissue sarcomas in adults. New Engl J Med. 2005;353:701−711.

Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004;54:94−109.

Dei Tos AP. Classification of pleomorphic sarcomas: where are we now? Histopathology. 2006 ;48:51−62.

Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013 Jul 1;31(19):2485-92. Epub 2013 May 28.

Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013 Jun1;31(16):2024-20248. Epub 2013 Apr 8.

George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 1;27(19):3154−3160. Epub 2009 May 18.

Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013 Jun 20;31(18):2296-2302. Epub 2013 Apr 29.

Le Cesne A, Domont J, Cioffi A, et al. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. Drugs Today (Barc). 2009;45:403−421.

Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 1;27:3133−3140.

Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. Virchows Arch. 2008 Feb;452(2):119−132. Epub 2007 Dec 14.

McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011 Apr 28;364(17):1595−1606. Epub 2011 Mar 16.

Nascimento AF, Raut CP. Diagnosis and management of pleomorphic sarcomas (so-called "MFH") in adults. J Surg Oncol. 2008;97:330−339.

National Comprehensive Cancer Network NCCN Clinical Cancer Guidelines in Oncology. Soft Tissue Sarcoma. V.1.2013. Accessed at www.nccn.org on October 11, 2013.

Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). Accessed at www.ncbi.nlm.nih.gov/sites/entrez?db=omim on March 15, 2010.

PDQ Cancer Information Summaries: Adult Soft Tissue Sarcoma Treatment. 2/15/2013. Accessed at http://www.cancer.gov/cancertopics/pdq/treatment/adult-soft-tissue-sarcoma/HealthProfessional/page1 on October 11, 2013.

Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011 Feb;22(2):452−457. Epub 2010 Jul 9.

Ries LAG, Ward KC, Young JL. Sarcomas. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007.

Rosai J. Soft Tissues. In: Rosai and Ackerman’s Surgical Pathology. Mosby, London, 2004 2237−2373.

Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):371-82. Epub 2013 Mar 8.

Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010 Feb 10;28(5):835−840. Epub 2010 Jan 4.

van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-1886. Epub 2012 May 16.